Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Contract Formulation Company Profile – SP Formulations

By Drug Discovery Trends Editor | April 13, 2009

SP Formulations
SP Formulations


Headquarters
Wareham, MA


Location(s)
Massachusetts and Hungary


Years in Drug Formulation
2 Years


Spokesperson
Tom Bradshaw, President


Web site 














Areas of research

•

Small Molecule  

•

Biological     Other

 





















































Drug Formulation Services Offered
• Analytical method development    • Bioavailability enhancement

•

Compatibility studies of active ingredients   

•

Dosage form selection

•

Excipient compatibility   

•

Formulation optimization

•

Formulation stress testing      in silico studies

•

Manufacture of clinical supplies   

•

Novel delivery system

•

Packaging compatibility assessment      Particle size reduction

•

Preclinical studies   

•

Solubilizing water-insoluble drugs

•

Stability studies      Taste masking/flavorings

 


 


 


 


 


 


 


 


 









































Other Services Offered
  Disease Research      Target Identification
  Lead Identification      Early Safety Tests
  Lead Optimization      Pre-clinical Studies
  IND Submission      Clinical Trials
  NDA Submission      Post-marketing Studies
      

 

 

 


 


 


 


 


 


 














Types of Drugs

•

Generics  

•

Prescription  

•

OTC

 



































Dosage Forms
• Capsules    • Implantable
  Inhalation   

•

Injectible

•

Oral   

•

Parenteral

•

Peptide and Protein   

•

Tablets

•

Topical       

 


 


 


 


 


 


Company’s role in drug discovery and developmnet
SP Formulations has an exciting combination of broad dose form capability for pre-clinical and clinical dose preparation as well as capabilities in both the US and Europe. Sterile or injectible drugs are our strong point with lyophilization process development as well as formulation capabilities. We have sterile filling capabilities in the US ( Massachusetts) as well as Hungary. We also have strong analytical support (FDA inspected GMP/GLP) through SynomicsPharma Services at our Wareham site. We can manage your project from preformulation studies to final dose form release for clinical trials in either US or Europe.


Company’s experience and expertise in drug formulation
Our staff is very experienced in sterile, injectable, semi solid and solid dose form drug development. The leader of our technology group is Dr. Marcel Langenauer, who has over 20 years of development and commercial topical and solid drug development experience with two Swiss pharmaceutical companies, one as managing director.


Relationship with pharma companies
With clearly defined drug delivery parameters from our clients, we scope out our recommended development pathway keeping in mind the issues that could be troublesome in dealing with regulatory authorities. We structure the formulation programs so that we go from simple proof of concept to more complete formulations as our clients succeed with in vitro and in vivo testing. Timeliness, communication and responsiveness are key to our project management success.


Factors critical for drug formulation
A robust analytical strategy, good understanding of drug solubility, formulation stability and bioavailability are the key factors. Of course the desired delivery profile along with the dose form is also essential. An early screening process to define the range of concentrations possible and the early DMPK profile will help steer us in our later formulation work. Usually we can accomplish this early screening and formulation development in a four week time.


Scientific/business/regulatory trends impacting drug formulation
Perhaps the most important trend is the movement to large molecules and the related formulation issues. This and the decreased solubility of many new drug candidates make formulation a challenge.


Whereas biotechs and pharma have sought approval in the US as their first goal, now many biotechs are seeing the advantages of European development or development in other regions such as Eastern or Central Europe, and India/China/Brazil. Each of these areas can offer benefits of speed, partners, lower costs, and other benefits over the traditional venues. With the FDA-drug approval process becoming more difficult and slower, companies are looking for ways to succeed that are faster and less expensive.


Success story
One of our most rewarding success stories involved the development of a depot formulation for a client looking for a release profile on the order of 21 days. Using non-proprietary methods, we were able develop a simple formulation which allowed the client to show ‘proof-of-concept’ in animal models; thus facilitating additional funding for their program.


How will roles of CROs and contract manufacturers change over the next few years?
There is clearly a trend to place complete projects with a single CRO (less individual studies; more complete drug development projects). The highly fragmented CRO marketplace (over 1000 companies; the top twenty companies representing less than 50% of market) there will be increased pressure to consolidate in the CRO space.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE